In conclusion, miR-191-5p alleviates Aβ1-42-induced microglia cell injury by targeting Map3k12 to inactivate the MAPK signaling, which may provide promising therapeutic biomarkers for AD treatment. This evidence concerns the gene MAP3K12 and Alzheimer disease.